Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDOncternal Therap Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Oncternal Therap Earnings Date And Information
Oncternal Therap last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-2.86 earnings per share for the quarter, topping analysts' consensus estimates of $-3.22 by $0.36. The company had revenue of 0 for the quarter and had revenue of 785.00 K for the year. Oncternal Therap has generated $-13 earnings per share over the last year ($-13.43 diluted earnings per share) and currently has a price-to-earnings ratio of -0.04. Oncternal Therap has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Oncternal Therap Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$3.22 | -$2.86 | 0.36 | $275.00 K | $0 |
| 08/08/2024 | Q2 2024 | -$3.03 | -$2.89 | 0.14 | $212.50 K | $801.00 K |
| 05/09/2024 | Q1 2024 | -$2.88 | -$2.83 | 0.05 | N/A | $569.00 K |
| 03/07/2024 | Q4 2023 | -$3.09 | -$3.11 | -0.02 | N/A | $297.00 K |
| 11/09/2023 | Q3 2023 | -$3.00 | -$3.35 | -0.35 | $125.00 K | $179.00 K |
| 08/10/2023 | Q2 2023 | -$3.40 | -$3.05 | 0.35 | $170.83 K | $106.00 K |
| 05/04/2023 | Q1 2023 | -$4.20 | -$3.93 | 0.27 | $166.67 K | $0 |
| 04/28/2023 | Q4 2022 | N/A | -$3.85 | N/A | $331.50 K | $171.00 K |
| 11/03/2022 | Q3 2022 | -$4.80 | -$0.67 | 4.13 | $325.00 K | $382.00 K |
| 08/09/2022 | Q2 2022 | -$4.60 | -$0.72 | 3.88 | $459.00 K | $191.00 K |
| 05/05/2022 | Q1 2022 | -$3.80 | -$0.61 | 3.19 | $525.00 K | $746.00 K |
| 03/10/2022 | Q4 2021 | -$5.00 | -$0.50 | 4.5 | $1.06 M | $556.00 K |
| 11/04/2021 | Q3 2021 | -$3.20 | -$0.60 | 2.6 | $1.30 M | $2.13 M |
| 08/05/2021 | Q2 2021 | -$2.80 | -$0.48 | 2.32 | $1.09 M | $883.00 K |
| 05/06/2021 | Q1 2021 | -$2.00 | -$0.37 | 1.63 | $1.11 M | $748.00 K |
| 03/11/2021 | Q4 2020 | -$3.60 | -$0.09 | 3.51 | $587.50 K | $1.59 M |
| 11/04/2020 | Q3 2020 | -$6.00 | -$0.22 | 5.78 | $623.00 K | $585.00 K |
| 08/06/2020 | Q2 2020 | N/A | -$0.34 | N/A | N/A | $623.00 K |
| 05/07/2020 | Q1 2020 | N/A | -$0.31 | N/A | N/A | $578.00 K |
| 03/16/2020 | Q4 2019 | N/A | -$0.27 | N/A | N/A | $736.00 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Oncternal Therap Earnings: FAQ's
In the previous quarter, Oncternal Therap (:ONCT) reported $-2.86 earnings per share (EPS) to beat the analysts' consensus estimate of $-3.22 by $0.36.
The conference call for Oncternal Therap's latest earnings report can be listened to online.
The conference call transcript for Oncternal Therap's latest earnings report can be read online.
Oncternal Therap (:ONCT) has a recorded annual revenue of $785.00 K.
Oncternal Therap (:ONCT) has a recorded net income of $-39,479,000.Oncternal Therap has generated $-13.43 earnings per share over the last four quarters.
Oncternal Therap (:ONCT) has a price-to-earnings ratio of -0.04 and price/earnings-to-growth ratio is -0.01.